ACTHAR: FDA-APPROVED as adjunct therapy for short-term administration in psoriatic arthritis

  • Psoriatic arthritis (PsA) is a complicated disorder involving 2 chronic conditions: inflammatory arthritis and psoriasis1
  • Research has shown that chronic PsA can cause joint damage2

Getting started is simple

Acthar is FDA-approved as an adjunctive therapy for short-term administration during acute episodes or exacerbations in psoriatic arthritis.3

It’s important that patients get their Acthar treatment as quickly as possible. Here’s how we help with that process in just 3 steps:

Step 1

  • Complete the Acthar Start Form and fax it to the Acthar Hub at 1-877-937-2284

Step 2

  • The Acthar Hub faxes back a confirmation and contacts the office within 4 business hours to explain next steps, including prior authorization requirements

Step 3

  • The Acthar Hub may contact the office staff with questions. Responding in a timely manner helps ensure patients get access to Acthar as soon as possible

If You Have Any Questions, Contact the Acthar Hub

The Case Manager at the Acthar Hub will keep office staff and patients informed about the status of their prescription.

Support Anytime From the Patient & Acthar Coaching Team (ActharPACT)

  • To supplement your efforts, patients have access to a 24-hour nurse hotline, a website, and follow-up support:

Be sure to let your patients know to expect welcome calls from the Acthar Hub and ActharPACT.


SEE More


  • Acthar should never be administered intravenously
  • Administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of Acthar
  • Acthar is contraindicated where congenital infections are suspected in infants
  • Acthar is contraindicated in patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction or sensitivity to proteins of porcine origins


SEE More

H.P. Acthar® Gel (repository corticotropin injection) is an adrenocorticotropic hormone (ACTH) analogue used for:

  • Treatment during an exacerbation or as maintenance therapy in selected cases of systemic dermatomyositis (polymyositis)
  • Treatment during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus
  • The treatment of symptomatic sarcoidosis
  • Adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)